Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, BIOSCIENCE HEALTH INNOVATIONS INC. reported revenue of $6M, up 208.3% year over year. Operating margin was 12.6% and net margin 11.3%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from BHIC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $6M | 12.6% | 11.3% |
| FY2024 | $2M | 4.7% | 4.7% |
| FY2023 | $1M | -42.1% | -42.1% |
| FY2022 | $0M | -245.8% | -245.8% |
| FY2021 | $0M | n/a | n/a |
How does BHIC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.